Cargando…

Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis

BACKGROUND: Clostridioides difficile infection (CDI) affected an estimated 365,000 persons in the United States in 2017. Despite a nationally decreasing trend of CDI cases, the population incidence of recurrent CDI (rCDI) has not improved. Elderly individuals (aged ≥ 65 years) are at higher risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Winnie W, Scott, Takara A, Boules, Mena, Teigland, Christie, Parente, Alexis, Unni, Sudhir, Feuerstadt, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394752/
https://www.ncbi.nlm.nih.gov/pubmed/33703939
http://dx.doi.org/10.18553/jmcp.2021.20395
_version_ 1785083438470004736
author Nelson, Winnie W
Scott, Takara A
Boules, Mena
Teigland, Christie
Parente, Alexis
Unni, Sudhir
Feuerstadt, Paul
author_facet Nelson, Winnie W
Scott, Takara A
Boules, Mena
Teigland, Christie
Parente, Alexis
Unni, Sudhir
Feuerstadt, Paul
author_sort Nelson, Winnie W
collection PubMed
description BACKGROUND: Clostridioides difficile infection (CDI) affected an estimated 365,000 persons in the United States in 2017. Despite a nationally decreasing trend of CDI cases, the population incidence of recurrent CDI (rCDI) has not improved. Elderly individuals (aged ≥ 65 years) are at higher risk of CDI, rCDI, and complicated CDI compared with younger individuals. OBJECTIVE: To analyze Medicare fee-for-service data for 12 months after an initial CDI episode, in order to obtain real-world data on health care resource utilization (HRU) and costs for elderly patients with CDI and rCDI. METHODS: A retrospective cohort study of patients who were aged ≥ 65 years and had a first (index) CDI diagnosis from January 1, 2010, to December 31, 2016, and continuous enrollment in Medicare Parts A, B, and D during the 12-month pre-index and 12-month post-index periods was conducted. A CDI episode was identified by either an inpatient stay with CDI diagnosis code or an outpatient medical claim with a CDI diagnosis code plus a CDI treatment. Each CDI episode was followed by a 14-day CDI claim-free period after the last CDI claim or end of CDI treatment. rCDI was a second or subsequent episode of CDI that occurred within an 8-week window after the 14-day CDI claim-free period. The number of CDI and rCDI episodes, HRU, time to recurrence, and total all-cause direct medical costs were calculated over the 12-month pre-index (baseline) and 12-month follow-up periods and stratified by number of rCDI episodes (No rCDI, 1 rCDI, 2 rCDI, 3+ rCDI). RESULTS: A total of 268,762 patients with an index CDI were included. Mean age was 78.3 years, and 69.0% were female. HRU was higher during the 6 months immediately pre-index versus 7-12 months pre-index, including a higher proportion of patients with a hospital admission (55.1% vs. 27.5%) or emergency department visit (41.3% vs. 27.4%), respectively. Moreover, 34.7% of the study population experienced rCDI. Of those who experienced 1 recurrence, 59.1% had a second recurrence, and of those who had 2 recurrences, 58.4% had a third. During the 12-month follow-up, postacute care was used by at least 70% of each rCDI cohort. The proportion of patients with ≥ 4 hospital admissions during follow-up was highest for the 3+ rCDI cohort (24.9% of patients). During the 12-month follow-up, mean total all-cause direct costs were $76,024, $99,348, $96,148, and $96,517 for the No rCDI, 1 rCDI, 2 rCDI, and 3+ rCDI cohorts, respectively, largely driven by inpatient costs. Adjusted all-cause total costs were significantly higher for all 3 rCDI cohorts compared with the No rCDI cohort. CONCLUSIONS: Elderly individuals experienced high rates of recurrence after their first CDI episode, and especially after a prior recurrence. The intensity of HRU during follow-up was higher for patients who suffered recurrences. Patients with rCDI had the burden of higher costs of care, including the patient out-of-pocket responsibility, versus patients with a single CDI episode.
format Online
Article
Text
id pubmed-10394752
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-103947522023-08-03 Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis Nelson, Winnie W Scott, Takara A Boules, Mena Teigland, Christie Parente, Alexis Unni, Sudhir Feuerstadt, Paul J Manag Care Spec Pharm Research BACKGROUND: Clostridioides difficile infection (CDI) affected an estimated 365,000 persons in the United States in 2017. Despite a nationally decreasing trend of CDI cases, the population incidence of recurrent CDI (rCDI) has not improved. Elderly individuals (aged ≥ 65 years) are at higher risk of CDI, rCDI, and complicated CDI compared with younger individuals. OBJECTIVE: To analyze Medicare fee-for-service data for 12 months after an initial CDI episode, in order to obtain real-world data on health care resource utilization (HRU) and costs for elderly patients with CDI and rCDI. METHODS: A retrospective cohort study of patients who were aged ≥ 65 years and had a first (index) CDI diagnosis from January 1, 2010, to December 31, 2016, and continuous enrollment in Medicare Parts A, B, and D during the 12-month pre-index and 12-month post-index periods was conducted. A CDI episode was identified by either an inpatient stay with CDI diagnosis code or an outpatient medical claim with a CDI diagnosis code plus a CDI treatment. Each CDI episode was followed by a 14-day CDI claim-free period after the last CDI claim or end of CDI treatment. rCDI was a second or subsequent episode of CDI that occurred within an 8-week window after the 14-day CDI claim-free period. The number of CDI and rCDI episodes, HRU, time to recurrence, and total all-cause direct medical costs were calculated over the 12-month pre-index (baseline) and 12-month follow-up periods and stratified by number of rCDI episodes (No rCDI, 1 rCDI, 2 rCDI, 3+ rCDI). RESULTS: A total of 268,762 patients with an index CDI were included. Mean age was 78.3 years, and 69.0% were female. HRU was higher during the 6 months immediately pre-index versus 7-12 months pre-index, including a higher proportion of patients with a hospital admission (55.1% vs. 27.5%) or emergency department visit (41.3% vs. 27.4%), respectively. Moreover, 34.7% of the study population experienced rCDI. Of those who experienced 1 recurrence, 59.1% had a second recurrence, and of those who had 2 recurrences, 58.4% had a third. During the 12-month follow-up, postacute care was used by at least 70% of each rCDI cohort. The proportion of patients with ≥ 4 hospital admissions during follow-up was highest for the 3+ rCDI cohort (24.9% of patients). During the 12-month follow-up, mean total all-cause direct costs were $76,024, $99,348, $96,148, and $96,517 for the No rCDI, 1 rCDI, 2 rCDI, and 3+ rCDI cohorts, respectively, largely driven by inpatient costs. Adjusted all-cause total costs were significantly higher for all 3 rCDI cohorts compared with the No rCDI cohort. CONCLUSIONS: Elderly individuals experienced high rates of recurrence after their first CDI episode, and especially after a prior recurrence. The intensity of HRU during follow-up was higher for patients who suffered recurrences. Patients with rCDI had the burden of higher costs of care, including the patient out-of-pocket responsibility, versus patients with a single CDI episode. Academy of Managed Care Pharmacy 2021-07 /pmc/articles/PMC10394752/ /pubmed/33703939 http://dx.doi.org/10.18553/jmcp.2021.20395 Text en Copyright © 2021, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research
Nelson, Winnie W
Scott, Takara A
Boules, Mena
Teigland, Christie
Parente, Alexis
Unni, Sudhir
Feuerstadt, Paul
Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis
title Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis
title_full Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis
title_fullStr Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis
title_full_unstemmed Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis
title_short Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis
title_sort health care resource utilization and costs of recurrent clostridioides difficile infection in the elderly: a real-world claims analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394752/
https://www.ncbi.nlm.nih.gov/pubmed/33703939
http://dx.doi.org/10.18553/jmcp.2021.20395
work_keys_str_mv AT nelsonwinniew healthcareresourceutilizationandcostsofrecurrentclostridioidesdifficileinfectionintheelderlyarealworldclaimsanalysis
AT scotttakaraa healthcareresourceutilizationandcostsofrecurrentclostridioidesdifficileinfectionintheelderlyarealworldclaimsanalysis
AT boulesmena healthcareresourceutilizationandcostsofrecurrentclostridioidesdifficileinfectionintheelderlyarealworldclaimsanalysis
AT teiglandchristie healthcareresourceutilizationandcostsofrecurrentclostridioidesdifficileinfectionintheelderlyarealworldclaimsanalysis
AT parentealexis healthcareresourceutilizationandcostsofrecurrentclostridioidesdifficileinfectionintheelderlyarealworldclaimsanalysis
AT unnisudhir healthcareresourceutilizationandcostsofrecurrentclostridioidesdifficileinfectionintheelderlyarealworldclaimsanalysis
AT feuerstadtpaul healthcareresourceutilizationandcostsofrecurrentclostridioidesdifficileinfectionintheelderlyarealworldclaimsanalysis